Compare
CV Sciences, Inc. vs Pyxis Oncology, Inc. vs Arbutus Biopharma Corp vs Opus Genetics, Inc.
| Latest fiscal year | CV Sciences, Inc. CVSI | Pyxis Oncology, Inc. PYXS | Arbutus Biopharma Corp ABUS | Opus Genetics, Inc. IRD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $13.79M | $13.86M | $14.08M | $14.20M |
| Revenue growth (YoY) | -12.2% | -14.2% | +128.2% | +29.1% |
| Gross margin | 49.0% | 82.8% (computed) | n/a | n/a |
| Operating margin | -3.4% | -609.2% | -271.0% | -271.9% |
| Net margin | -6.9% | -574.5% | -237.9% | -349.3% |
| Net income | -$958.0K | -$79.62M | -$33.50M | -$49.59M |
| EPS (Diluted) | -$0.01 | -$1.28 | -$0.17 | -$0.80 |
| Operating cash flow | -$407.0K | -$63.50M | -$39.64M | -$35.25M |
| Free cash flow | -$516.0K | -$63.51M | -$39.64M | n/a |
| Cash & equivalents | n/a | $15.42M | $18.01M | $45.09M |
| Total assets | $6.96M | $91.52M | $94.62M | $50.24M |
| Total liabilities | $5.49M | $38.11M | $18.04M | $34.90M |
| Shareholders' equity | $1.47M | $53.41M | $76.58M | $15.35M |
| Return on year-end equity | -65.3% | -149.1% | -43.7% | -323.1% |
| Shares outstanding | 184.26M | 62.69M | 192.53M | 69.89M |
Revenue, most recent five fiscal years
| Fiscal year | CV Sciences, Inc. | Pyxis Oncology, Inc. | Arbutus Biopharma Corp | Opus Genetics, Inc. |
|---|---|---|---|---|
| Latest | $13.79M Ended 2025-12-31 | $13.86M Ended 2025-12-31 | $14.08M Ended 2025-12-31 | $14.20M Ended 2025-12-31 |
| 1 year earlier | $15.71M Ended 2024-12-31 | $16.15M Ended 2024-12-31 | $6.17M Ended 2024-12-31 | $10.99M Ended 2024-12-31 |
| 2 years earlier | $16.00M Ended 2023-12-31 | n/a | $18.14M Ended 2023-12-31 | $19.05M Ended 2023-12-31 |
| 3 years earlier | $16.20M Ended 2022-12-31 | n/a | $39.02M Ended 2022-12-31 | $39.85M Ended 2022-12-31 |
| 4 years earlier | $20.05M Ended 2021-12-31 | n/a | $10.99M Ended 2021-12-31 | $589.0K Ended 2021-12-31 |